← Leaderboards
David Richard Light
Illexcor Therapeutics, Llc
$5,339,332
Attributed
$5,339,332
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,339,332 · 4
By mechanism
R44$4,745,673 · 2
R43$593,659 · 2
Top collaborators
No co-investigators on record.
Most similar at Illexcor Therapeutics, Llc
Same institution · by research overlap
- James Burnett$599,962
Others in their field
Other Emerging Leaders on “Efficacy Study”
- Kimberly Smith · Ppd Development Lp$115,671,664
- Beth Baseler · Leidos Biomedical Research, Inc.$75,287,834
- Yunda Huang · Fred Hutchinson Cancer Center$72,814,726
- Susan Abushakra · Alzheon, Inc.$50,765,244
- Julie Ake · National Institute Of Allergy And Infectious Diseases$50,742,120
- Thomas Rudge · Battelle Centers/Pub Hlth Res & Evaluatn$42,989,272
Research focus
Efficacy StudyAcutePharmaceutical PreparationsCessation Of LifeIn VivoExposure ToHourAffectHypoxiaHemoglobinDoseAldehydesOrgan FailureAmericanAffinityInnovationClinical TrialsVanillinWhole BloodHistopathologyOxygenNovel TherapeuticsAnimalsLife
Grant awards (8)
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$798,351
R44 · FY2025 · HL · contact PI
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$529,259
R44 · FY2025 · HL · contact PI
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$887,907
R44 · FY2024 · HL · contact PI
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$807,795
R44 · FY2024 · HL · contact PI
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$976,740
R44 · FY2023 · HL · contact PI
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$745,621
R44 · FY2023 · HL · contact PI
Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier$298,412
R43 · FY2021 · HL · contact PI
Pharmacologic Inhibition of NLRP3 Inflammasome-Dependent Injury following Vaso-occlusion in Sickle Cell Disease$295,247
R43 · FY2021 · HL · contact PI